Compare Honeywell International Inc (HON) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Zimmer Biomet Holdings Inc — how do they compare? Honeywell International Inc trades at $207.77 (market cap $65.48B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Honeywell International Inc is far larger — about 3.9× Zimmer Biomet Holdings Inc's market cap, and Honeywell International Inc pays the higher dividend (1.36%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HON | ZBH | |
|---|---|---|
Market Cap | $65.48B | $16.95B |
Volume | 2,047,782 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $248.79 | $103.98 |
52-Week Low | $188.14 | $79.58 |
Typical Hold Time | 91 Days | 89 Days |
Enterprise Value | $90.27B | $24.02B |
Dividend Yield | 1.36% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.12 with minimal daily movement, showing strong profitability metrics including 21.6% net margin and 47.4% ROE. The company recently completed a strategic split into three focused businesses and secured a $300 million refinery project, positioning for growth in automation. Technical indicators show bearish momentum with support at $205 and resistance at $208, while fundamentals reveal attractive valuation with P/E of 7.9x below industry averages.
HON presents a compelling value opportunity with analyst consensus target of $259.25 representing 25% upside potential. The company's post-spin growth story is gaining momentum with recent earnings beats, though investors should monitor debt levels that have increased to 47.7% of assets and potential execution risks from the corporate restructuring.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
